Key Highlights

  • 0.21 is the loss per share in USD implied by the consensus EPS estimate of -0.21 for Milestone Pharmaceuticals Inc. (NASDAQ:MIST), which reports third quarter 2026 results before the market opens on November 13, 2026.
  • 0.56 million USD was second quarter 2026 net CARDAMYST revenue, versus zero a year earlier, while the net loss widened to USD 28.6 million, or USD 0.21 per share, from USD 13.0 million, or USD 0.20.
  • 170.6 million USD was cash, equivalents and short-term investments at June 30, 2026, up from USD 106.0 million, and management expects it to fund operating expenses and Capital Expenditure into the second half of 2027.
  • 82.44 million USD is the market Capitalization per the screener snapshot, below USD 100 million, against an USD 81.8 million Royalty financing obligation and USD 59.2 million of convertible notes at June 30, 2026.

What Investors Expect From Milestone Pharmaceuticals Inc. (NASDAQ:MIST) on November 13, 2026

Per the screener snapshot, Milestone Pharmaceuticals Inc. reports third quarter 2026 results on November 13, 2026, before the market opens, with a consensus EPS estimate of -0.21 and a market capitalization of USD 82.44 million. The estimate matches the second quarter loss of USD 0.21 per share. Investors will watch CARDAMYST prescriptions, which started with a mid-February 2026 launch. A third quarter 2025 comparison was not found in published coverage, and the call time was not detailed in the snapshot.

The Rationale: Last Reported Quarter and Management Outlook for Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

In the second quarter, SG&A rose to USD 22.6 million from USD 8.9 million, Research and Development was USD 3.5 million versus USD 3.7 million, and cost of product sales was USD 0.03 million. The six-month net loss was USD 54.7 million, or USD 0.41 per share. More than 800 prescribers had started patients, up from about 200, with more than 1,500 scripts filled for more than 1,300 patients and commercial covered lives rising from about 25% to about 50%. Management plans first enrollment in the ReVeRA-301 Phase 3 trial in the second half of 2026 and expects an EMA decision in the first half of 2027.

Valuation, Liquidity and Risks for Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

Cash of USD 170.6 million exceeds the snapshot market capitalization of USD 82.44 million by about USD 88.2 million (calculated), but the royalty obligation and convertible notes total USD 141.0 million (calculated). Shares outstanding were 124,497,980 plus 16,412,925 pre-funded warrants. Risks include launch pace, rising selling costs, dilution, financing obligations and trial outcomes. At a Market Value below USD 100 million, small-cap stocks can be volatile and illiquid. A China NDA is under review with no decision date found in published coverage.

Where Things Stand

Where things stand: Milestone Pharmaceuticals Inc. (NASDAQ:MIST) reports with a consensus EPS estimate of -0.21, a snapshot market capitalization of USD 82.44 million and USD 170.6 million of cash at June 30, 2026. Second quarter product Revenue of USD 0.56 million was small against SG&A of USD 22.6 million, so launch traction is the main variable. Prescriber growth, coverage near 50% and the ReVeRA-301 start in the second half of 2026 are the operating markers, while financing obligations of USD 141.0 million add context. The call time has not been confirmed beyond the before-open flag in the snapshot. This is information only and not Investment advice.